<?xml version="1.0" encoding="UTF-8" standalone="yes"?><response><header><requestMsgID></requestMsgID><responseTime>2025-11-17 18:38:31.3831</responseTime><responseMsgID></responseMsgID><successYN>Y</successYN><resultCode>00</resultCode><resultMsg>NORMAL SERVICE.</resultMsg></header><body><item><biblioSummaryInfoArray><biblioSummaryInfo><applicationDate>2009.03.10</applicationDate><applicationFlag>특허</applicationFlag><applicationNumber>10-2024-7039506</applicationNumber><claimCount>1</claimCount><examinerName> </examinerName><finalDisposal> </finalDisposal><inventionTitle>항-ＨＥＲ２ 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법</inventionTitle><inventionTitleEng>Combinations of an anti-HER2 antibody-drug conjugate and  chemotherapeutic agents, and methods of use</inventionTitleEng><openDate>2024.12.03</openDate><openNumber>10-2024-0170596</openNumber><originalApplicationDate>2009.03.10</originalApplicationDate><originalApplicationKind>국제출원/분할</originalApplicationKind><originalApplicationNumber>10-2023-7011861</originalApplicationNumber><originalExaminationRequestDate>2024.12.27</originalExaminationRequestDate><originalExaminationRequestFlag>Y</originalExaminationRequestFlag><publicationDate> </publicationDate><publicationNumber> </publicationNumber><registerDate> </registerDate><registerNumber> </registerNumber><registerStatus>공개</registerStatus><translationSubmitDate>2024.11.27</translationSubmitDate></biblioSummaryInfo></biblioSummaryInfoArray><ipcInfoArray><ipcInfo><ipcDate>(2017.01.01)</ipcDate><ipcNumber>A61K 47/68</ipcNumber></ipcInfo><ipcInfo><ipcDate>(2006.01.01)</ipcDate><ipcNumber>A61K 31/5365</ipcNumber></ipcInfo><ipcInfo><ipcDate>(2006.01.01)</ipcDate><ipcNumber>A61K 31/517</ipcNumber></ipcInfo><ipcInfo><ipcDate>(2006.01.01)</ipcDate><ipcNumber>A61K 45/06</ipcNumber></ipcInfo><ipcInfo><ipcDate>(2006.01.01)</ipcDate><ipcNumber>A61P 35/00</ipcNumber></ipcInfo><ipcInfo><ipcDate>(2006.01.01)</ipcDate><ipcNumber>C07K 16/32</ipcNumber></ipcInfo></ipcInfoArray><familyInfoArray><familyInfo><familyApplicationNumber>1020237011861</familyApplicationNumber></familyInfo></familyInfoArray><abstractInfoArray><abstractInfo><astrtCont> 항체-약물 접합체 트라스투주마브-MCC-DM1과 화학요법제 (그의 입체 이성체, 기하 이성체, 호변체, 용매화물, 대사물 및 제약상 허용되는 염 포함)의 병용물은 종양 세포 성장을 억제하고, HER2 및 KDR (VEGFR 수용체 1)에 의해 매개된 암과 같은 장애를 치료하는 데에 유용하다. 이러한 병용물을 포유류 세포에서 상기 장애, 또는 관련 병적 상태를 시험관내, 계내, 및 생체내 진단, 예방 또는 치료하는 데 사용하는 방법이 본원에 기재되어 있다. </astrtCont></abstractInfo></abstractInfoArray><internationalInfoArray><internationalInfo><internationOpenDate>2009.09.24</internationOpenDate><internationOpenNumber>WO2009117277</internationOpenNumber><internationalApplicationDate>2009.03.10</internationalApplicationDate><internationalApplicationNumber>PCT/US2009/036608</internationalApplicationNumber></internationalInfo></internationalInfoArray><claimInfoArray><claimInfo><claim>1. 치료 유효량의 트라스투주마브(trastuzumab)-MCC-DM1(T-DM1) 및 치료 유효량의 5-FU을 포함하는 치료적 병용물로, 상기 치료적 병용물은 복합 제형으로서 또는 교대로 투여되는 것인, ErbB2 발현 암의 치료를 위한 치료적 병용물의 용도.</claim></claimInfo></claimInfoArray><applicantInfoArray><applicantInfo><address>미합중국 캘리포니아 (우편번호 *****-****) 사우쓰샌프란시스코 디엔에이 웨이 *</address><code>519987054940</code><country>미국</country><engName>GENENTECH, INC.</engName><name>제넨테크, 인크.</name></applicantInfo></applicantInfoArray><inventorInfoArray><inventorInfo><address>미국 ***** 캘리포니아주 사우...</address><code> </code><country>미국</country><engName>BERRY, Leanne</engName><name>베리, 레안</name></inventorInfo><inventorInfo><address>미국 ***** 캘리포니아...</address><code> </code><country>미국</country><engName>PHILLIPS, Gail, Lewis</engName><name>필립스, 게일, 루이스</name></inventorInfo><inventorInfo><address>미국 ***** 캘리포니...</address><code> </code><country>미국</country><engName>SLIWKOWSKI, Mark, X.</engName><name>슬리우코우스키, 마크, 엑스.</name></inventorInfo></inventorInfoArray><agentInfoArray><agentInfo><address>서울 중구 정동길 **-** (정동, 정동빌딩) **층(김.장법률사무소)</address><code>919980003836</code><country>대한민국</country><engName>LEE, Kuiy Dong</engName><name>이귀동</name></agentInfo><agentInfo><address>서울특별시 종로구 사직로*길 **, *층 (내자동)(김.장 법률사무소)</address><code>919980005034</code><country>대한민국</country><engName>CHANG, Duck Soon</engName><name>장덕순</name></agentInfo></agentInfoArray><priorityInfoArray><priorityInfo><priorityApplicationCountry>미국</priorityApplicationCountry><priorityApplicationDate>2008.03.18</priorityApplicationDate><priorityApplicationNumber>61/037,410</priorityApplicationNumber></priorityInfo></priorityInfoArray><designatedStateInfoArray/><priorArtDocumentsInfoArray/><legalStatusInfoArray><legalStatusInfo><commonCodeName>수리 (Accepted) </commonCodeName><documentEngName>[Divisional Application(International Application)] Patent Application</documentEngName><documentName>[분할출원(국제출원)]특허출원서</documentName><receiptDate>2024.11.27</receiptDate><receiptNumber>1-1-2024-1312062-50</receiptNumber></legalStatusInfo><legalStatusInfo><commonCodeName>수리 (Accepted) </commonCodeName><documentEngName> </documentEngName><documentName>[심사청구]심사청구서·우선심사신청서</documentName><receiptDate>2024.12.27</receiptDate><receiptNumber>1-1-2024-1449084-22</receiptNumber></legalStatusInfo></legalStatusInfoArray><imagePathInfo><docName>1020247039506.jpg</docName><largePath>http://plus.kipris.or.kr/kiprisplusws/fileToss.jsp?arg=6c650beb4cee9ce4122b704b88878c9343d148be82cc5e90b65494c1d50db4101c27122946dfa20cdf6fd0ae5f9cce105df90ab38da7ce32c08803b3477ff3f189917c2f03d55009</largePath><path>http://plus.kipris.or.kr/kiprisplusws/fileToss.jsp?arg=ed43a0609e94d6e22d01c5c32ba711cfa1ba6a15d813ca4ee35f909b074d3c81b1344354006ca6825f86628830eb9d542c2336fa0657d57392c75e4d3bdf1960950face935006995</path></imagePathInfo><rndInfoArray/></item></body><count><numOfRows>1</numOfRows><pageNo>1</pageNo><totalCount>1</totalCount></count></response>